{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:14:03Z","timestamp":1792142043545,"version":"4.4.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Merck KGaA, Darmstadt, Germany","award":["MS200059_0013"],"award-info":[{"award-number":["MS200059_0013"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>STUDY QUESTION<\/jats:title>\n                  <jats:p>What is the agreement between antral follicle count (AFC) and anti-M\u00fcllerian hormone (AMH) levels when used to patient classification according to the Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) criteria?<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>SUMMARY ANSWER<\/jats:title>\n                  <jats:p>Our study indicates a strong agreement between the AFC and the AMH levels in classifying POSEIDON patients; thus, either can be used for this purpose, although one in four women will have discordant values when both biomarkers are used<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WHAT IS KNOWN ALREADY<\/jats:title>\n                  <jats:p>According to the POSEIDON criteria, both AFC and AMH may be used to classify low-prognosis patients. Proposed AFC and AMH thresholds of 5 and 1.2\u2009ng\/ml, respectively, have their basis in published literature; however, no study has yet determined the reproducibility of patient classification in comparing one biomarker with the other, nor have their thresholds ever been validated within this patient population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY DESIGN, SIZE, DURATION<\/jats:title>\n                  <jats:p>A population-based cohort study involving 9484 consecutive patients treated in three fertility clinics in Brazil, Turkey and Vietnam between 2015 and 2017.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n                  <jats:p>Participants were infertile women between 22 and 46\u2009years old in their first in vitro fertilization\/intracytoplasmic sperm injection cycle of standard ovarian stimulation with exogenous gonadotropins whose baseline ovarian reserves had been assessed by both AFC and AMH. Details of pre- and post-treatment findings were input into a coded research file. Two indicators of interest were created to classify patients according to the POSEIDON criteria based upon AFC and AMH values. Patients who did not fit any of the four POSEIDON groups were classified as non-POSEIDON. AFC was determined in the early follicular phase using two-dimensional (2D) transvaginal ultrasonography, whereas AMH values were based on the modified Beckman Coulter generation II enzyme-linked immunosorbent assay. Agreement rates were computed between AFC and AMH to classify patients using Cohen\u2019s kappa statistics. Logistic regression analyzes were carried out to examine the association between ovarian markers and low (&amp;lt;4) and suboptimal (4\u20139) oocyte yield.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n                  <jats:p>The degree of agreement in classifying patients according to POSEIDON groups was strong overall (kappa = 0.802; 95% CI: 0.792\u20130.811). A total of 73.8% of individuals were classified under the same group using both biomarkers. The disagreement rates were \u223c26% and did not diverge when AFC or AMH was used as the primary biomarker criterion. Significant regression equations were found between ovarian markers and oocyte yield (P\u2009&amp;lt;\u20090.0001). For low oocyte yield, the optimal AFC and AMH cutoff values were 5 and 1.27\u2009ng\/ml with sensitivities of 0.61 and 0.66, specificities of 0.81 and 0.72, and AUC receiver operating characteristics of 0.791 and 0.751, respectively. For suboptimal oocyte yield respective AFC and AMH cutoffs were 12 and 2.97\u2009ng\/ml with sensitivities of 0.74 and 0.69, specificities of 0.76 and 0.66 and AUCs of 0.81 and 0.80.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n                  <jats:p>Our study relied on 2D transvaginal sonography to quantify the AFC and manual Gen II assay for AMH determination and classification of patients. AMH data must be interpreted in an assay-specific manner. Treatment protocols varied across centers potentially affecting patient classification.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n                  <jats:p>Three of four patients will be classified the same using either AFC or AMH values. Both biomarkers provide acceptable and equivalent accuracy in predicting oocyte yield further supporting their use and proposed thresholds in daily clinical practice for patient classification according to the POSEIDON criteria. However, the sensitivity of POSEIDON thresholds in predicting low oocyte yield is low. Clinicians should adopt the biomarker that may best reflect their clinical setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n                  <jats:p>Unrestricted investigator-sponsored study grant (MS200059_0013) from Merck KGaA, Darmstadt, Germany. The funder had no role in study design, data collection, analysis, decision to publish or manuscript preparation. S.C.E. declares receipt of unrestricted research grants from Merck and lecture fees from Merck and Med.E.A. H.Y. declares receipt of payment for lectures from Merck and Ferring. L.N.V. receives speaker fees and conferences from Merck, Merck Sharp and Dohme (MSD) and Ferring and research grants from MSD and Ferring. T.M.H. received speaker fees and conferences from Merck, MSD and Ferring. The remaining authors have nothing to disclose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>TRIAL REGISTRATION NUMBER<\/jats:title>\n                  <jats:p>not applicable.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/humrep\/deab056","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T20:12:58Z","timestamp":1614197578000},"page":"1530-1541","source":"Crossref","is-referenced-by-count":33,"title":["Antral follicle count and anti-M\u00fcllerian hormone to classify low-prognosis women under the POSEIDON criteria: a classification agreement study of over 9000 patients"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1313-9680","authenticated-orcid":false,"given":"Sandro C","family":"Esteves","sequence":"first","affiliation":[{"name":"ANDROFERT, Andrology and Human Reproduction Clinic, Campinas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3170-0566","authenticated-orcid":false,"given":"Hakan","family":"Yarali","sequence":"additional","affiliation":[{"name":"Anatolia IVF, Ankara, Turkey"},{"name":"Department of Obstetrics and Gynecology, Hacettepe University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6529-6912","authenticated-orcid":false,"given":"Lan N","family":"Vuong","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"},{"name":"IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam"},{"name":"HOPE Research Center, My Duc Hospital, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 F","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Statistika Consulting, Campinas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8302-5147","authenticated-orcid":false,"given":"\u0130rem Y","family":"\u00d6zbek","sequence":"additional","affiliation":[{"name":"Anatolia IVF, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7215-2316","authenticated-orcid":false,"given":"Mehtap","family":"Polat","sequence":"additional","affiliation":[{"name":"Anatolia IVF, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6149-170X","authenticated-orcid":false,"given":"Ho L","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"},{"name":"IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-2274","authenticated-orcid":false,"given":"Toan D","family":"Pham","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"},{"name":"IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3528-7358","authenticated-orcid":false,"given":"Tuong M","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"},{"name":"IVFMD, My Duc Hospital, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"key":"2021070807482254400_deab056-B1","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.fertnstert.2016.02.005","article-title":"A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept","volume":"105","author":"Alviggi","year":"2016","journal-title":"Fertil Steril"},{"key":"2021070807482254400_deab056-B2","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1093\/humrep\/der318","article-title":"Predictive factors of ovarian response and clinical outcome after IVF\/ICSI following a rFSH\/GnRH antagonist protocol with or without oral contraceptive pre-treatment","volume":"26","author":"Andersen","year":"2011","journal-title":"Hum Reprod"},{"key":"2021070807482254400_deab056-B3","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.fertnstert.2012.12.048","article-title":"Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients","volume":"99","author":"Arce","year":"2013","journal-title":"Fertil Steril"},{"key":"2021070807482254400_deab056-B4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/humupd\/dmr039","article-title":"Ovarian antral folliculogenesis during the human menstrual cycle: a review","volume":"18","author":"Baerwald","year":"2012","journal-title":"Hum Reprod Update"},{"key":"2021070807482254400_deab056-B5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.fertnstert.2018.03.031","article-title":"Multicenter evaluation of the access AMH antim\u00fcllerian hormone assay for the prediction of antral follicle count and poor ovarian response to controlled ovarian stimulation","volume":"110","author":"Baker","year":"2018","journal-title":"Fertil Steril"},{"key":"2021070807482254400_deab056-B6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s43032-020-00300-9","article-title":"Human menopausal gonadotropin commenced on early follicular period increases live birth rates in POSEIDON group 3 and 4 poor responders","volume":"28","author":"Berker","year":"2021","journal-title":"Reprod Sci"},{"key":"2021070807482254400_deab056-B7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/humupd\/dml034","article-title":"A systematic review of tests predicting ovarian reserve and IVF outcome","volume":"12","author":"Broekmans","year":"2006","journal-title":"Hum Reprod Update"},{"key":"2021070807482254400_deab056-B8","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.fertnstert.2009.04.040","article-title":"The antral follicle count: practical recommendations for better standardization","volume":"94","author":"Broekmans","year":"2010","journal-title":"Fertil Steril"},{"key":"2021070807482254400_deab056-B9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.fertnstert.2007.12.013","article-title":"The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count","volume":"91","author":"Broer","year":"2009","journal-title":"Fertil Steril"},{"key":"2021070807482254400_deab056-B10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/GCO.0b013e3283384911","article-title":"The role of anti-M\u00fcllerian hormone assessment in assisted reproductive technology outcome","volume":"22","author":"Broer","year":"2010","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2021070807482254400_deab056-B11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/humupd\/dms041","article-title":"Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach","volume":"19","author":"Broer","year":"2013","journal-title":"Hum Reprod Update"},{"key":"2021070807482254400_deab056-B12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fendo.2020.00181","article-title":"Follicular output rate and Follicle-to-Oocyte Index of low prognosis patients according to POSEIDON criteria: a retrospective cohort study of 32,128 treatment cycles","volume":"11","author":"Chen","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021070807482254400_deab056-B13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3389\/fendo.2019.00800","article-title":"Dehydroepiandrosterone supplementation improves the outcomes of in vitro fertilization cycles in older patients with diminished ovarian reserve","volume":"10","author":"Chen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021070807482254400_deab056-B14","doi-asserted-by":"crossref","first-page":"e0235707","DOI":"10.1371\/journal.pone.0235707","article-title":"Dual-trigger improves the outcomes of in vitro fertilization cycles in older patients with diminished ovarian reserve: a retrospective cohort study","volume":"15","author":"Chern","year":"2020","journal-title":"PLoS One"},{"key":"2021070807482254400_deab056-B15","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.fertnstert.2014.10.052","article-title":"Modification of the Beckman-Coulter second-generation enzyme-linked immunosorbent assay protocol improves the reliability of serum antim\u00fcllerian hormone measurement","volume":"103","author":"Craciunas","year":"2015","journal-title":"Fertil Steril"},{"key":"2021070807482254400_deab056-B16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/uog.6310","article-title":"Intraobserver and interobserver reliability of automated antral follicle counts made using three-dimensional ultrasound and SonoAVC","volume":"33","author":"Deb","year":"2009","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2021070807482254400_deab056-B17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3389\/fendo.2018.00361","article-title":"The effect of dose adjustments in a subsequent cycle of women with suboptimal response following conventional ovarian stimulation","volume":"9","author":"Drakopoulos","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021070807482254400_deab056-B18","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1093\/humrep\/dez181","article-title":"Oocyte quantity, as well as oocyte quality, plays a significant role for the cumulative live birth rate of a POSEIDON criteria patient","volume":"34","author":"Esteves","year":"2019","journal-title":"Hum Reprod"},{"key":"2021070807482254400_deab056-B19","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3389\/fendo.2019.00814","article-title":"The POSEIDON criteria and its measure of success through the eyes of clinicians and embryologists","volume":"10","author":"Esteves","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021070807482254400_deab056-B20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fendo.2019.00917","article-title":"Validation of ART calculator for predicting the number of metaphase II oocytes required for obtaining at least one euploid blastocyst for transfer in couples undergoing in vitro fertilization\/intracytoplasmic sperm injection","volume":"10","author":"Esteves","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021070807482254400_deab056-B21","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/humrep\/der092","article-title":"ESHRE consensus on the definition of \u2018poor response\u2019 to ovarian stimulation for in vitro fertilization: the Bologna criteria","volume":"26","author":"Ferraretti","year":"2011","journal-title":"Hum Reprod"},{"key":"2021070807482254400_deab056-B22","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1515\/cclm-2014-0022","article-title":"First fully automated immunoassay for anti-M\u00fcllerian hormone","volume":"52","author":"Gassner","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"2021070807482254400_deab056-B23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3389\/fendo.2019.00281","article-title":"A. Ovarian reserve markers to identify poor responders in the context of POSEIDON classification","volume":"10","author":"Grisendi","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021070807482254400_deab056-B24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0015-0282(03)00741-6","article-title":"Reproductive aging and variability in the ovarian antral follicle count: application in the clinical setting","volume":"80","author":"Hansen","year":"2003","journal-title":"Fertil Steril"},{"key":"2021070807482254400_deab056-B25","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.12688\/f1000research.10382.1","article-title":"The novel POSEIDON stratification of \u2018Low prognosis patients in Assisted Reproductive Technology\u2019 and its proposed marker of successful outcome","volume":"5","author":"Humaidan","year":"2016","journal-title":"F1000Res"},{"key":"2021070807482254400_deab056-B26","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/humupd\/dmu062","article-title":"Technical and performance characteristics of anti-M\u00fcllerian hormone and antral follicle count as biomarkers of ovarian response","volume":"21","author":"Iliodromiti","year":"2015","journal-title":"Hum Reprod Update"},{"key":"2021070807482254400_deab056-B27","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.fertnstert.2008.10.042","article-title":"A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation","volume":"93","author":"Jayaprakasan","year":"2010","journal-title":"Fertil Steril"},{"key":"2021070807482254400_deab056-B28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/uog.3913","article-title":"The interobserver reliability of off-line antral follicle counts made from stored three-dimensional ultrasound data: a comparative study of different measurement techniques","volume":"29","author":"Jayaprakasan","year":"2007","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2021070807482254400_deab056-B29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jclinepi.2010.03.002","article-title":"Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were proposed","volume":"64","author":"Kottner","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2021070807482254400_deab056-B30","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.fertnstert.2007.07.1293","article-title":"Evaluation of anti-Mullerian hormone as a test for the prediction of ovarian reserve","volume":"90","author":"Kwee","year":"2008","journal-title":"Fertil Steril"},{"key":"2021070807482254400_deab056-B31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/humupd\/dmp036","article-title":"Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART)","volume":"16","author":"La Marca","year":"2010","journal-title":"Hum Reprod Update"},{"key":"2021070807482254400_deab056-B32","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/humupd\/dmt037","article-title":"Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice","volume":"20","author":"La Marca","year":"2014","journal-title":"Hum Reprod Update"},{"key":"2021070807482254400_deab056-B33","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/humrep\/dez051","article-title":"Cumulative live birth rates in low-prognosis women","volume":"34","author":"Leijdekkers","year":"2019","journal-title":". Hum Reprod"},{"key":"2021070807482254400_deab056-B34","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3389\/fendo.2019.00642","article-title":"Cumulative live birth rates in low prognosis patients according to the POSEIDON criteria: an analysis of 26,697 cycles of in vitro fertilization\/intracytoplasmic sperm injection","volume":"10","author":"Li","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021070807482254400_deab056-B35","doi-asserted-by":"crossref","first-page":"9354","DOI":"10.18632\/aging.103210","article-title":"Efficacies of different ovarian hyperstimulation protocols in poor ovarian responders classified by the POSEIDON criteria","volume":"12","author":"Li","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"2021070807482254400_deab056-B36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"2021070807482254400_deab056-B37","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.7863\/jum.2005.24.9.1279","article-title":"Intraobserver and interobserver reproducibility of ovarian volume, antral follicle count, and vascularity indices obtained with transvaginal 3-dimensional ultrasonography, power Doppler angiography, and the virtual organ computer-aided analysis imaging program","volume":"24","author":"Merc\u00e9","year":"2005","journal-title":"J Ultrasound Med"},{"key":"2021070807482254400_deab056-B38","author":"MHRA","year":"2013"},{"key":"2021070807482254400_deab056-B39","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1471-0528.2005.00670.x","article-title":"Antral follicle count, anti-Mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology?","volume":"112","author":"Muttukrishna","year":"2005","journal-title":"BJOG"},{"key":"2021070807482254400_deab056-B40","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1093\/humrep\/dem285","article-title":"The ISMAAR proposal on terminology for ovarian stimulation for IVF","volume":"22","author":"Nargund","year":"2007","journal-title":"Hum Reprod"},{"key":"2021070807482254400_deab056-B41","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.fertnstert.2012.11.051","article-title":"Biomarkers of ovarian response: current and future applications","volume":"99","author":"Nelson","year":"2013","journal-title":"Fertil Steril"},{"key":"2021070807482254400_deab056-B42","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.fertnstert.2014.12.114","article-title":"Comparison of antim\u00fcllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials","volume":"103","author":"Nelson","year":"2015","journal-title":"Fertil Steril"},{"key":"2021070807482254400_deab056-B43","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3389\/fendo.2019.00409","article-title":"Cumulative live birth rates of Good and low prognosis patients according to POSEIDON criteria: a single center analysis of 18,455 treatment cycles","volume":"10","author":"Shi","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021070807482254400_deab056-B44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/09513590.2017.1291614","article-title":"Inter-cycle and inter-observer variability of the antral follicle count in routine clinical practice","volume":"33","author":"Subir\u00e1","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"2021070807482254400_deab056-B45","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ajog.2017.02.027","article-title":"Ovarian reserve testing: a user's guide","volume":"217","author":"Tal","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"2021070807482254400_deab056-B46","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00404-014-3332-3","article-title":"Predictive value of anti-m\u00fcllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF\/ET","volume":"290","author":"Tsakos","year":"2014","journal-title":"Arch Gynecol Obstet"},{"key":"2021070807482254400_deab056-B47","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fendo.2018.00317","article-title":"Double stimulation in the same ovarian cycle (DuoStim) to maximize the number of oocytes retrieved from poor prognosis patients: a multicenter experience and SWOT analysis","volume":"9","author":"Vaiarelli","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2021070807482254400_deab056-B48","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1093\/humrep\/deaa203","article-title":"The euploid blastocysts obtained after luteal phase stimulation show the same clinical, obstetric and perinatal outcomes as follicular phase stimulation-derived ones: a multicenter study","volume":"35","author":"Vaiarelli","year":"2020","journal-title":"Hum Reprod"},{"key":"2021070807482254400_deab056-B49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa1703768","article-title":"IVF transfer of fresh or frozen embryos in women without polycystic ovaries","volume":"378","author":"Vuong","year":"2018","journal-title":"N Engl J Med"},{"key":"2021070807482254400_deab056-B50","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/humrep\/deu036","article-title":"A single-centre evaluation of two new anti-Mullerian hormone assays and comparison with the current clinical standard assay","volume":"29","author":"Welsh","year":"2014","journal-title":"Hum Reprod"},{"key":"2021070807482254400_deab056-B51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12958-018-0343-0","article-title":"Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial","volume":"16","author":"Xu","year":"2018","journal-title":"Reprod Biol Endocrinol"},{"key":"2021070807482254400_deab056-B52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.repbio.2013.04.005","article-title":"Within-laboratory and between-laboratory variability in the measurement of anti-mullerian hormone determined within an external quality assurance scheme","volume":"13","author":"Zuvela","year":"2013","journal-title":"Reprod Biol"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/6\/1530\/37948129\/deab056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/36\/6\/1530\/37948129\/deab056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T15:15:09Z","timestamp":1625757309000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/36\/6\/1530\/6209120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,4,2]]},"published-print":{"date-parts":[[2021,5,17]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deab056","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,4,2]]}}}